SLC7A11 and breast carcinoma: In a similar way, a newer VLP vaccine that displays the third extracellular domain of xCT (ECD3), whose sequence is longer than that of ECD6, resulting in a major oligoclonal antibody response, can neutralize xCT function and impair breast cancer cell proliferation and metastasization [61].